Baxter International Hits 52-Week Low as Stock Plummets to $17.00

Baxter International, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low, trading at USD 17.00 as of March 9, 2026. This significant drop reflects a challenging year for the company, with a staggering 45.55% decline in its stock price over the past year, contrasting sharply with the S&P 500's 17.78% gain during the same period. The company's financial metrics reveal a P/E ratio of 28.00 and a dividend yield of 1.78%. However, Baxter's performance indicators raise concerns, including a high debt-to-equity ratio of 1.23 and a return on equity of just 4.23%. The company has reported negative results for three consecutive quarters, with operating cash flow at its lowest point of USD 765 million and net sales declining by 26.29% to USD 2,810 million. Additionally, pre-tax profits have plummeted by 45.07%. Baxter's long-term growth prospects appear weak, with a compound annual growth rate (CAGR) of operating profits declining by 17.50% over the last five years. The stock's performance has consistently lagged behind the S&P 500, indicating ongoing challenges in the market.